This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Cyclacel Pharma

BOSTON ( TheStreet) -- An email from John R. kicks off this week's Biotech Stock Mailbag:

"Hi Adam, what do you think of Leerink Swann's recent upgrade of Cyclacel Pharmaceuticals(CYCC - Get Report) to outperform with a $3 price target last month? Stock closed today at another new 52-week low (70 cents after hours.) Do you think it's even worth a look when it hits cash levels, or around $0.55? Or should this one should just be in the dumper? I have some free capital and was looking at possibly pulling the trigger."

It's entirely appropriate to tie together Leerink's July 12 initiation of research coverage of Cyclacel with an outperform rating and a $3 price target with the same bank's role in leading a financing of Cyclacel on July 1 that raised $9.3 million, net of fees and expenses.

I'm told that some of Cyclacel's existing institutional shareholders weren't happy with the latest financing and didn't participate as a result. The Leerink deal might have been easy money but it raised too little and did nothing to improve the quality or stability of the company's shareholder base. In fact, the Leerink financing probably did the opposite, which has contributed to the stock's accelerated decline in value this summer. [The market crash isn't helping, either.]

Cyclacel still needs to raise more money, but will now be forced to go hat in hand to Wall Street with a weaker share price and less or no support from old shareholders who could have helped the company attract new shareholders.

Cyclacel is also saddled with a messy capital and governance structure that gives preferred shareholders too much control over the company's board. This is a legacy issue that Cyclacel should have fixed but hasn't.

I agree that Cyclacel's stock price is cheap and undervalued. Cyclacel should not carry an enterprise value half the size of competitor Sunesis Pharmaceuticals (SNSS - Get Report), for example. But Cyclacel's stock is stuck in the muck and merely pointing out a relative valuation discrepancy isn't going to get it unstuck. Investors view data from the phase III study of sapacitabine in elderly AML patients as too far away to matter right now. If management wants to fix its stock price today, they should start by landing a licensing deal for one of its drugs. The validation would be a big confidence boost and the money from a partner would be a big help, too. Fix the capital structure and do the hard work necessary to bring in a better base of long-term institutional shareholders.
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMRN $1.34 4.70%
AVNR $16.96 0.00%
CYCC $0.32 -3.00%
SNSS $0.70 -2.00%
AAPL $95.24 0.26%


Chart of I:DJI
DOW 16,044.27 +29.89 0.19%
S&P 500 1,866.09 +13.88 0.75%
NASDAQ 4,329.1020 +60.3390 1.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs